



Regulus Therapeutics Inc.
 Investor Relations Department
 10614 Science Center Dr
 San Diego, CA 92121
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: RGLS

Last Trade:	1.38
Trade Time:	4:00 PM ET May 26, 2017
Change:	0.03 ↑ (+1.852%)
Day Range	1.33 - 1.45
52-Week Range	0.94 - 6.25
Volume	2,100,553

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting *microRNAs*. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced *microRNA* therapeutics pipeline complemented by a maturing *microMarkers*SM biomarkers platform and a rich intellectual property estate to retain its leadership in the *microRNA* field. Regulus is developing RG-101, a GalNAc-conjugated anti-miR targeting *microRNA*-122 for the tre... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 4, 2017
[Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring](#)
- Apr 27, 2017
[Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017](#)
- Mar 28, 2017
[Regulus to Present at the 16th Annual Needham Healthcare Conference](#)
- Mar 2, 2017
[Regulus Reports Fourth Quarter 2016 Financial Results and Pipeline Update](#)
- Feb 23, 2017
[Regulus to Release Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 3, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 5, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 3, 2016
[Quarterly Report \(10-Q\)](#)